Vera-llonch M et al. - Abatacept is cost-effective by current standards of medical practice in patients with moderately to severely active RA and inadequate response to an anti-TNF Methods
Study to assess cost-effectiveness of abatacept in RA pts (women aged 55-64 yrs) with inadequate response to anti-TNF
At model entry, pts were assumed to receive either oral DMARD only or oral DMARD plus abatacept
Pts were then tracked from model entry until death
Future health-state utilities and medical-care costs were estimated based on predicted values of the HAQ-DI
The model was estimated using data from a Phase III clinical trial of abatacept plus secondary sources
Cost-effectiveness was expressed in terms of incremental cost/QALY gained alternatively over 10 yrs and a lifetime
Future costs and health effects were discounted at 3% annually
Results
Over 10 yrs, abatacept would yield 1.0 additional QALY/ patient at an incremental cost of $45,497 over a lifetime
Cost-effectiveness was $50,576 per QALY gained over 10 yrs, and $45,979 per QALY gained over a lifetime
See all
